PLC Medical Systems, Inc. is developing RenalGuard™ with a team of physicians and engineers with the objective of providing a solution to the complex challenge of Contrast-Induced Nephropathy, a form of Acute Renal Failure. It is a novel, yet simple approach aiming to advance the care of patients with renal-insufficiency undergoing imaging procedures.

What is CIN? Contrast-Induced Nephropathy (CIN) is a form of Acute Renal Failure caused by exposure to contrast media during image-guided cardiology and radiology procedures. The lack of effective treatment to prevent CIN remains problematic for patients with renal-insufficiency.

Our Solution RenalGuard Therapy™ is designed to reduce the toxic effects that contrast media can have on the kidneys for patients undergoing imaging procedures. This therapy is based on the theory that creating and maintaining a high urine output allows the body to rapidly eliminate contrast, reducing its toxic effects.

Clinical Investigations are planned to establish the safety and effectiveness of RenalGuard Therapy in reducing the incidence of Contrast-Induced Nephropathy (CIN) in high-risk patients.  RenalGuard System is not intended for the infusion of blood, blood components, medications, or nutritional fluids, nor have any investigations been carried out on patients with congestive heart failure (CHF) or acute cardiac instability.

This site contains medical information that is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns.